18 and older, any sex, with Varicose Veins or Venous Stasis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Venous Haemodynamics - Percent Change in Time Averaged Mean Velocity TAMVPrimary· 0 and 6 weeks
Assessment of change in venous flow utilising Time Averaged Mean Velocity (TAMV) (measured in cm/s), assessed as percentage change from baseline.
0 weeks
Group
Value
95% CI
Group A
3.36
-16.48 – 18.54
Group B
26.58
6.65 – 92.32
Group C
39.49
20.48 – 99.75
6 weeks
Group
Value
95% CI
Group A
0.46
-20.81 – 12.26
Group B
27.83
8.01 – 70.93
Group C
36.38
6.45 – 108.80
Venous Flow Parameters - PVSecondary· 0 and 6 weeks
Assessment of change in venous flow utilising Peak Velocity (PV) (measured in cm/s), assessed as percentage change from baseline.
0 Week
Group
Value
95% CI
Group A
-4.760
-25.84 – 12.61
Group B
202.7
82.63 – 247.1
Group C
151.9
111.3 – 234.7
6 Weeks
Group
Value
95% CI
Group A
3.360
-17.91 – 15.13
Group B
145.8
62.97 – 233.5
Group C
246.6
84.66 – 297.5
Venous Flow Parameters - VFSecondary· 0 and 6 weeks
Assessment of change in venous flow utilising Volume Flow (VF) (measured in cc/min), assessed as percentage change from baseline.
0 weeks
Group
Value
95% CI
Group A
5.525
-14.76 – 22.48
Group B
28.81
16.59 – 87.42
Group C
52.82
16.99 – 92.54
6 weeks
Group
Value
95% CI
Group A
-6.145
-22.58 – 10.21
Group B
29.11
5.768 – 84.21
Group C
52.82
16.99 – 92.54
Venous Clinical SeveritySecondary· 0 and 6 weeks.
Clinical severity of venous disease as measured by the venous clinical severity score (VCSS). Scale measure from 0-30, with higher values indicating worse status. It is made up of 10 variables scored from 0-3
0 weeks
Group
Value
95% CI
Group A
6
4.5 – 8
Group B
6
5 – 8
Group C
7
4.750 – 9.250
6 weeks
Group
Value
95% CI
Group A
7
5 – 9.5
Group B
5
4 – 8
Group C
3
2 – 6.5
Disease Specific Quality of LifeSecondary· 0 weeks and 6 weeks
quality of life as assessed on the Aberdeen varicose vein questionnaire scale (0-100). This is a patient reported quality of life measure, which assesses symptoms of varicose veins. Higher values are worse.
0 weeks
Group
Value
95% CI
Group A
18.62
10.13 – 26.83
Group B
21.07
16.34 – 29.47
Group C
21.30
11.91 – 31.33
6 weeks
Group
Value
95% CI
Group A
19.72
11.30 – 25.38
Group B
18.86
14.99 – 28.52
Group C
15.01
11.04 – 21.31
Sponsor's own description
This study is designed to describe the difference in varicose vein outcomes found from using a neuromuscular electrical stimulation device for different amounts of time - Group A (control - no device), Group B (device for 30 mins per day) and Group C (device for 60 mins per day). The groups are assessed after 6 weeks of intervention.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT05410912 — Varicose Vein in Patients Under the Age of 40
· active not recruiting
NCT04231942 — Elastic Compression Stockings and Varicose Veins Recurrence
· NA
· active not recruiting
Other Imperial College London trials
Trials by the same sponsor.
NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH
· NA
· not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
· Phase 1
· not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing
· NA
· not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy
· Phase 2
· not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 31 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03850496.